RxDoctor Payments Data

David Roberson, MD

Otolaryngology · Milford, DENPI 1447221015

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 13 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Cochlear Americas at 53.9% of the total. That places this record below the midpoint for otolaryngology clinicians in DE, where the typical reported total is $1,648.

$787in general payments, 2019–2025

Across 13 payments — averaging $60.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cochlear Americas$425
  • AstraZeneca$250
  • Johnson & Johnson$44
  • Regeneron Healthcare Solutions, Inc.$28
  • Smith+Nephew$27
  • Olympus America Inc.$13

What the payments were for

  • Food & beverage$787100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$787 in reported general payments places this provider in the 35th percentile of 27 otolaryngology providers in Delaware.

See all otolaryngology providers in Delaware

Medicare billing

Part B allowed, 2024
$137,838
Medicare patients
689
Services billed
1,433

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Azelastine Hcl159$6,421
Fluticasone Propionate344$4,938
Ipratropium Bromide165$4,798
Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth32$4,225
Mometasone Furoate53$2,985
Azelastine-FluticasoneAzelastine/Fluticasone21$2,640
Levocetirizine Dihydrochloride33$1,239
Montelukast Sodium36$936
Pantoprazole Sodium63$797
Esomeprazole Magnesium12$669
Fluocinolone Acetonide Oil21$528
Omeprazole26$393
Famotidine25$315
Meclizine Hcl14$149

Paid to pharmacies, not to this prescriber.

Other otolaryngology in Milford

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →